Sight Sciences Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
SGHT$10.75-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
(in thousands, except share data)
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at June 30, 2024 | 50,136,131 | $50 | $424,973 | $(323,385) | $101,638 |
| Issuance of common stock upon exercise of stock options | 38,936 | — | 77 | — | 77 |
| Issuance of common stock upon vesting of restricted stock units | 223,081 | — | — | — | — |
| Stock-based compensation expense | — | — | 4,308 | — | 4,308 |
| Net loss | — | — | — | (11,066) | (11,066) |
| Balance at September 30, 2024 | 50,398,148 | 50 | 429,358 | (334,451) | 94,957 |
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at December 31, 2023 | 49,131,363 | $49 | $414,956 | $(294,790) | $120,215 |
| Issuance of common stock upon exercise of stock options | 194,119 | — | 233 | — | 233 |
| Issuance of common stock upon vesting of restricted stock units | 840,376 | 1 | (1) | — | — |
| Withholding taxes on net share settlement of restricted stock units | — | — | (20) | — | (20) |
| Warrant issuance | — | — | 609 | — | 609 |
| Employee stock purchase plan purchases | 232,290 | — | 450 | — | 450 |
| Stock-based compensation expense | — | — | 13,131 | — | 13,131 |
| Net loss | — | — | — | (39,661) | (39,661) |
| Balance at September 30, 2024 | 50,398,148 | 50 | 429,358 | (334,451) | 94,957 |
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at June 30, 2023 | 48,649,343 | $49 | $407,146 | $(271,064) | $136,131 |
| Issuance of common stock upon exercise of stock options | 60,738 | — | 117 | — | 117 |
| Issuance of common stock upon vesting of restricted stock units | 12,138 | — | — | — | — |
| Stock-based compensation expense | — | — | 3,856 | — | 3,856 |
| Net loss | — | — | — | (13,035) | (13,035) |
| Balance at September 30, 2023 | 48,722,219 | 49 | 411,119 | (284,099) | 127,069 |
| Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at December 31, 2022 | 48,298,138 | $48 | $399,271 | $(239,243) | $160,076 |
| Issuance of common stock upon exercise of stock options | 163,940 | — | 288 | — | 288 |
| Issuance of common stock upon vesting of restricted stock units | 181,607 | 1 | — | — | 1 |
| Withholding taxes of net share settlement of restricted stock units | — | — | (222) | — | (222) |
| Employee stock purchase plan purchases | 78,534 | — | 661 | — | 661 |
| Stock-based compensation expense | — | — | 11,121 | — | 11,121 |
| Net loss | — | — | — | (44,856) | (44,856) |
| Balance at September 30, 2023 | 48,722,219 | 49 | 411,119 | (284,099) | 127,069 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.